Objective To explore the application value of the prospective molecular classification tool(ProMisE)molecular typing for endometrial cancer in the prognosis assessment.Methods A retrospective a-nalysis was conducted on the clinical data of 150 patients with endometrial cancer admitted to the General Hospital of Ningxia Medical University.The patients were divided into 4 groups according to ProMisE molec-ular typing:DNA polymerase ε(POLE)mutant type,mismatch repair protein(MMR-d)type,p53 wild type(p53wt type)and p53 mutant type(p53abn type)were compared.The clinicopathological characteristics,treatment regimens and prognosis of patients in each group were compared.Results Endometrial cancer pa-tients with different ProMisE molecular subtypes showed differences in age,tumor histological type,depth of myometrial invasion,lymph node metastasis,etc.,and the differences were statistically significant(P<0.05).Patients with POLE mutations are younger,have a better degree of tumor differentiation,and have the best prognosis.Patients with p53abn type have a relatively advanced tumor stage and the poorest prognosis.The prognosis of patients with MMR-d type and p53wt type lies between the two.Conclusion ProMisE mo-lecular typing can provide an important basis for the prognosis assessment of patients with endometrial cancer and is helpful for formulating individualized and precise treatment plans.